Name | Eplivanserin |
---|---|
Synonyms |
4-[(1E,3Z)-3-{[2-(Dimethylamino)ethoxy]imino}-3-(2-fluorophenyl)-1-propen-1-yl]phenol
Ciltyri Eplivanserin 2-Propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-[2-(dimethylamino)ethyl]oxime, (1Z,2E)- 4-[(1E,3Z)-3-{[2-(dimethylamino)ethoxy]imino}-3-(2-fluorophenyl)prop-1-en-1-yl]phenol |
Description | Eplivanserin is a potent, selective and orally available 5-HT2 receptor antagonist, with an IC50 of 5.8 nM in rat cortical membrane, and a Kd of 1.14 nM. |
---|---|
Related Catalog | |
Target |
IC50: 5.8 nM (5-HT2 receptor, rat cortical membrane)[1] Kd: 1.14 nM (5-HT2 receptor)[1] |
In Vitro | Eplivanserin is a potent, selective and orally available 5-HT2 antagonist, with an IC50 of 5.8 nM in rat cortical membrane, and a Kd of 1.14 nM. Eplivanserin hemifumarate (SR 46349B) shows weak inhibition on other 5-HT kinases, with IC50s of 0.12 μM (Pig cortex 5-HT1C), 14 μM (Rat hippocampus 5-HT1A), and 16 μM (Rat stnatum 5-HT1B, Ox caudate nucleus 5-HT1D). Eplivanserin also has inhibitory effects on rat cortex adrenergic α1 and α2, rat whole brain histammine H1, Na+ channel, and rat striatum dopamine D1 and D2, with IC50s of 3.4 μM, 1.0 μM, 5.0 μM, 39 μM, 9 μM and 28 μM, respectively[1]. |
In Vivo | Eplivanserin hemifumarate (SR 46349B) inhibits 5-HT2 receptor binding of [3H]ketanserin with an ED50 of 0.087 mg/kg after i.p. injection, and 0.097 mg/kg after p.o administration in mice[1]. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 453.4±55.0 °C at 760 mmHg |
Molecular Formula | C19H21FN2O2 |
Molecular Weight | 328.381 |
Flash Point | 228.0±31.5 °C |
Exact Mass | 328.158691 |
PSA | 45.06000 |
LogP | 4.22 |
Vapour Pressure | 0.0±1.1 mmHg at 25°C |
Index of Refraction | 1.534 |
Storage condition | 2-8°C |